| 摘要 |
Disclosed are methyl ((1S)-1-(((2S)-2-(4-(4’-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)acetyl)-2-pyrrolidinyl)-4-chloro-1H-imidazol-5-yl)-4-biphenylyl)-1H-5-chloro-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate derivatives as represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is 0, 1, or 2; X is selected from hydrogen, alkenyl, cyano, cycloalkyl, (cycloalkyl)alkyl, halo, and heterocyclyl; R1 is selected from hydrogen and halo; R2 is selected from hydrogen, alkenyl, cyano, cycloalkyl, (cycloalkyl)alkyl, halo, and heterocyclyl; or R1 and R2, together with the carbon atoms to which they are attached, form a six-membered aromatic ring optionally substituted with one halo group; provided that at least one of X and R2 is selected from alkenyl, cyano, cycloalkyl, (cycloalkyl)alkyl, halo, and heterocyclyl; each R3 is alkyl, wherein the alkyl can optionally form a fused three- or four-membered ring with an adjacent carbon atom or a spirocyclic three- or four-membered ring with the carbon atom to which it is attached; wherein the fused and spirocyclic rings are optionally substituted with one or two alkyl groups; each R4 is independently selected from hydrogen and -C(O)R5; and each R5 is independently selected from alkoxy, alkyl, arylalkoxy, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, (NRcRd)alkenyl, and (NRcRd25 )alkyl; and wherein the remaining substituents are as defined herein. Further disclosed is a composition comprising a compound as defined above, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, and optionally further comprising at least one additional compound having anti-HCV activity, for treating an HCV infection in a patient. |
